Immix Biopharma, Inc. announced its 2nd positive IMX-110 interim update from the Company's ongoing Phase 1b/2a IMMINENT-01 (NCT05840835) study of IMX-110 in combination with BeiGene's anti-PD-1 antibody tislelizumab. "In the subsequent higher dose cohorts of IMX-110, the company are hopeful that clinical results will further improve. The optimal dose identified in IMMINENT-01 will be utilized in upcoming Phase 2IMMINENT-02 clinical trial investigating IMX-110 in combination With BeiGene anti-PD-1 antibody Tislelizumab in relapsed/refractory solid tumors, including relapsed/refractory colorectal cancer.

No dose limiting toxicities have been observed in the first 2 cohorts; the trial is now enrolling the next cohort of three patients at a higher dose of IMX-110 in combined with anti-PD-1 antibodytislelizumab. Tumor growth is assessed every 2 months. To put this clinical trial update in perspective, multi-kinase inhibitor regorafenib (marketed as STIVARGA®?

by Bayer) combined with best supportive care in relapsed/refractories metastatic colorectal cancer patients with median 3 prior lines of therapy produced progression free survival of 2 months and a 1% response rate according to the FDA approval label. This study was not a head-to-head evaluation with IMX-110 and differences exist between trial designs, subject characteristics, and caution should be exercised when evaluating clinical data across studies. IMMINENT-01 is an ongoing phase 1b/2a clinical trial combining tissue specific therapeutic IMX-110 with BeiGene anti-PD- 1 antibody tislelizumumab, in patients with relapsed/refractory Solid tumors.

The novel approach combining TSTx IMX-110 with anti-PD-1 antibodies tislelizumab is designed to expand the population of cancer patients experiencing extended remissions from immunotherapies by converting immunologically "cold" tumors "hot".